Blue Trust Inc. Has $358,000 Stake in Becton, Dickinson and Company $BDX

Blue Trust Inc. grew its position in Becton, Dickinson and Company (NYSE:BDX) by 6.3% during the 2nd quarter, Holdings Channel reports. The firm owned 2,078 shares of the medical instruments supplier’s stock after purchasing an additional 124 shares during the quarter. Blue Trust Inc.’s holdings in Becton, Dickinson and Company were worth $358,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northcape Wealth Management LLC boosted its position in Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after buying an additional 51 shares in the last quarter. Brady Family Wealth LLC boosted its holdings in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock worth $989,000 after acquiring an additional 53 shares in the last quarter. Diversified Trust Co boosted its holdings in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after acquiring an additional 53 shares in the last quarter. Horizon Bancorp Inc. IN boosted its holdings in shares of Becton, Dickinson and Company by 10.9% in the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 56 shares in the last quarter. Finally, Meadow Creek Wealth Advisors LLC boosted its stake in Becton, Dickinson and Company by 5.4% in the first quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock worth $266,000 after purchasing an additional 59 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on BDX. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price objective on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Piper Sandler reiterated a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Morgan Stanley upped their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Wells Fargo & Company upped their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Trading Up 0.1%

Shares of NYSE BDX opened at $186.76 on Tuesday. The company’s 50 day simple moving average is $190.23 and its 200 day simple moving average is $185.45. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The firm has a market capitalization of $53.53 billion, a P/E ratio of 33.59, a P/E/G ratio of 1.46 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion for the quarter. On average, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 over the last quarter. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.